The White House
November 6, 2025

I. A Historic Advance in Most-Favored-Nation Pricing

Today, President Donald J. Trump has announced a seminal achievement in his unwavering campaign to rectify the injustice of exorbitant prescription drug costs. The Administration has secured definitive agreements with the pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk, effecting a profound reduction in the prices Americans pay for several of the world’s most critical medications.

These agreements culminate in historic price reductions for the two drugs with the highest annual expenditures in the United States—essential treatments for millions of American adults contending with diabetes, cardiovascular conditions, obesity, and related comorbidities.

The specific terms of these transformative agreements are as follows:

• The prices of Ozempic® and Wegovy® will be reduced from $1,000 and $1,350 per month, respectively, to a singular price of $350 per month when procured through the TrumpRx initiative.

• The price of Zepbound®, alongside Orforglipron upon its regulatory approval, will fall from $1,086 per month to an average of $346 per month under TrumpRx.

• Should the FDA approve an oral formulation of Wegovy, or analogous GLP-1 pharmaceuticals from these companies, the introductory dosage will be available for $150 per month through TrumpRx.

The monumental price reductions negotiated under President Trump’s leadership will now enable Medicare and Medicaid to provide coverage for these vital obesity medications at a fraction of the cost to taxpayers previously proposed by the preceding administration.

• The Medicare pricing for Ozempic, Wegovy, Mounjaro, and Zepbound will be established at $245—less than half the cost proposed under the Biden Administration.

• State Medicaid programs will, for the first time, have access to these medications at these unprecedented price points.

• Medicare beneficiaries will benefit from a co-pay of merely $50 per month.

Furthermore, this accord extends to other essential medicines produced by Eli Lilly and Novo Nordisk, ensuring broad-based relief:

• Eli Lilly will provide Emgality®, a migraine treatment, at $299 per pen, representing a $443 reduction from the list price.

• Eli Lilly will offer Trulicity®, a widely prescribed diabetes medication, at $389 per month, a discount of $598.

• Novo Nordisk will make widely-used insulin products, including NovoLog® and Tresiba®, available for $35 per monthly supply.

Critically, the agreement stipulates that both corporations will guarantee Most-Favored-Nation pricing on all future pharmaceuticals brought to market, repatriate increased revenue from foreign sales of existing products, and extend MFN pricing access to every State Medicaid program across the nation.

II. Strategic Reinvestment in American Pharmaceutical Sovereignty

In a parallel commitment to fortifying the nation’s economic and health security, Eli Lilly and Novo Nordisk have announced substantial investments to expand domestic manufacturing capacity.

• Novo Nordisk has committed an additional $10 billion to strengthen its U.S. footprint, including end-to-end domestic production of the prospective Wegovy tablet.

• Under President Trump’s economic policies, Eli Lilly has announced a minimum of $27 billion in new U.S. manufacturing investments.

III. The “Make America Healthy Again” Initiative: A Foundational Approach

Today’s announcements represent a pivotal stride in President Trump’s “Make America Healthy Again” initiative, which seeks to promote national wellness by confronting the root causes of chronic disease.

• With the Centers for Disease Control and Prevention (CDC) estimating the prevalence of obesity among American adults at 40%, this condition stands as a primary driver of chronic illnesses, including type 2 diabetes, hypertension, heart disease, and certain cancers.

• By making these transformative medications accessible, the Administration is seizing a historic opportunity to reverse the obesity epidemic and its associated health crises, empowering Americans to achieve lasting health gains.

The Administration remains dedicated to a comprehensive strategy that realigns healthcare incentives, fosters private-sector innovation, elevates public awareness of nutrition and exercise, and advances critical medical research.

IV. Rectifying Global Imbalances in Pharmaceutical Commerce

President Trump is taking decisive action to rebalance a system that has permitted other wealthy nations to benefit from American pharmaceutical innovation at the direct expense of American patients.

• Recent data confirms that Americans pay more than three times the price for brand-name pharmaceuticals compared to other OECD nations, even after accounting for domestic discounts.

• While the United States constitutes less than five percent of the global population, it is the source of roughly 75% of global pharmaceutical profits.

• This disparity stems from a paradigm where manufacturers, having benefited from generous U.S. government research subsidies and healthcare expenditures, then discount their products abroad—effectively forcing American consumers to subsidize both manufacturer profits and foreign health systems.

V. Fulfilling a Commitment to American Patients First

President Trump is delivering on promises that the political establishment long deemed unattainable.

• On May 12, 2025, the President signed the Executive Order, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” directing the Administration to align American drug prices with those of peer nations.

• On July 31, 2025, President Trump communicated directly with leading pharmaceutical manufacturers, outlining the imperative to lower U.S. drug prices to match the lowest available in other developed countries.

• Since September 30, 2025, the President has announced five consequential agreements with major manufacturers, securing substantial price relief on numerous products for millions of Americans.

In the words of President Trump: “In case after case, our citizens pay massively higher prices than other nations for the very same pill, from the very same factory, effectively subsidizing socialism abroad with skyrocketing prices at home. We have spent tremendous amounts of money only to provide inexpensive drugs to other countries. The disparity is beyond anything—four times, five times different—and this injustice ends now.”

#TrumpWins #AmericaFirst #DrugPriceCuts #MostFavoredNation #Healthcare #MakeAmericaHealthyAgain #Obesity #Diabetes #CWEB @realDonaldTrump @EliLilly @NovoNordisk @CWEB